Valuation: Danaher Corporation

Market Cap 13TCr 12TCr 11TCr 10TCr 19TCr 12,96400Cr 19TCr 1,30600Cr 51TCr 6,37400Cr 51TCr 49TCr 22,03700Cr P/E 2026 *
32x
P/E 2027 * 25.6x
Enterprise Value 15TCr 14TCr 13TCr 12TCr 22TCr 14,90000Cr 22TCr 1,50100Cr 59TCr 7,32500Cr 58TCr 57TCr 25,32700Cr EV / Sales 2026 *
5.88x
EV / Sales 2027 * 5.25x
Free-Float
70.58%
Yield 2026 *
0.77%
Yield 2027 * 0.82%
Manager TitleAgeSince
Chief Executive Officer 62 01/09/2020
Director of Finance/CFO - 28/02/2026
Chief Tech/Sci/R&D Officer - 25/08/2025
Director TitleAgeSince
Director/Board Member 74 01/07/1999
Chairman 74 01/01/1984
Director/Board Member 69 01/01/1984
Change 5-day change 1-year change 3-year change Capi.($)
-0.78%+1.02% - - 13TCr
-0.71%+6.72%+18.80%-0.46% 21TCr
+1.65%-2.29%-31.94%+1.99% 12TCr
+1.54%+0.50%-58.31%-15.57% 6.58TCr
-1.42%-3.62%+3.29%-9.87% 4.76TCr
+3.03%-0.17%-26.91%-33.60% 4.44TCr
-0.84%+5.41%+15.30%+8.84% 3.91TCr
-2.02%+1.54%+23.68%+30.76% 3.68TCr
-1.41%+3.99%+77.58%+2.50% 2.94TCr
+1.76%-1.87%-29.03%-11.24% 2.82TCr
Average +0.08%+0.55%-0.84%-2.96% 6.91TCr
Weighted average by Cap. +0.01%+1.50%-2.87%-2.59%

Financials

2026 *2027 *
Net sales 2.63TCr 2.31TCr 2.15TCr 1.97TCr 3.7TCr 2,53300Cr 3.76TCr 26TCr 9.97TCr 1,24500Cr 9.87TCr 9.66TCr 4,30600Cr 2.84TCr 2.49TCr 2.32TCr 2.13TCr 3.99TCr 2,73100Cr 4.06TCr 28TCr 11TCr 1,34300Cr 11TCr 10TCr 4,64200Cr
Net income 422.22Cr 370.83Cr 344.87Cr 316.46Cr 594.6Cr 41TCr 603.77Cr 4.1TCr 1.6TCr 20TCr 1.59TCr 1.55TCr 69TCr 538.16Cr 472.67Cr 439.57Cr 403.36Cr 757.89Cr 52TCr 769.57Cr 5.22TCr 2.04TCr 25TCr 2.02TCr 1.98TCr 88TCr
Net Debt 2.01TCr 1.77TCr 1.64TCr 1.51TCr 2.83TCr 1,93500Cr 2.87TCr 19TCr 7.62TCr 95TCr 7.54TCr 7.38TCr 3,29000Cr 1.41TCr 1.24TCr 1.15TCr 1.06TCr 1.99TCr 1,36100Cr 2.02TCr 14TCr 5.36TCr 67TCr 5.31TCr 5.19TCr 2,31400Cr
Logo Danaher Corporation
Danaher Corporation is an industrial and technologic group organized around three families of products: - diagnostic equipment (40.5% of net sales); - life sciences equipment (29.8%); - biotechnology equipment (29.7%): ranging from basic biological research to the development and manufacturing of vaccines, biological drugs, cell and gene therapies, and new technologies such as mRNA. Net sales are distributed geographically as follows: the United States (40.6%), China (10.7%) and other (48.7%).
Employees
59,000
Trader
Investor
Global
Quality
ESG MSCI
-